In times of market volatility, it can be comforting for investors to rely on safe strategies that have proven to be successful in the past. But what should you do if those strategies are limiting your opportunity for market-beating gains?
For some investors, it may be time to consider investing in commodities. But trading commodities is different from trading stocks. And it’s not for the faint of heart.
On this week’s episode of the MarketBeat Podcast, Kate Stalter talks to Carley Garner. Garner is a commodity market analyst and broker at DeCarleyTrading.com who shares her view on the commodities market in 2022.
Some of the questions their conversation will cover include:
- What to expect from oil prices, and what do changes in oil prices mean for consumers?
- How can investors and traders capitalize on volatility in natural gas prices?
- Why gold and silver may not always behave the way you think they will?
That’s the kind of insight you’ll get from the MarketBeat Podcast. This weekly podcast is just 30 minutes long, making it an ideal companion for you to take on your daily walk or when you’re doing errands. The podcast features exclusive interviews from top traders, fund managers, market analysts, and asset managers just to name a few. Every week you’ll get actionable information that will help clarify what’s really going on in the market.
Simply subscribe to the MarketBeat Podcast from wherever you get your podcasts.
Apple Podcasts - Spotify - iHeart - Overcast - Amazon
Let’s all become smarter investors together. Subscribe to The MarketBeat Podcast today.
7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead
The biotechnology (biotech) sector was one of the best performing sectors in 2020. Many companies saw their stock prices rise as the race was on for a Covid-19 vaccine.
However, many of these companies were pre-revenue companies. Or they were companies that only had one or two in-market products or therapies. And as the calendar turned to 2021, investors took notice. And what went up quickly went down. And in the case of the biotech sector, it came down hard.
One way to tell is to look at biotech ETFs. One of the most popular ETFs, the VanEck Vectors Biotech ETF (NYSEARCA:BBH) is down more than 15%. So you can imagine what it’s been like for many individual biotech stocks. If you’re a buy-and-hold investor, you’re licking some wounds right about now.
But investors who knew what companies to buy have done well. And many of those names will continue to lead the biotech sector in 2022. In this special presentation, we give investors seven biotech stocks that represent different aspects of this diverse sector. We’re confident there’s something for investors of all risk tolerances. View the "7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead"